FDA Seeks Panel Feedback On Lung Tumor, Emphysema Device Applications
This article was originally published in The Gray Sheet
Executive Summary
Clinical data necessary to support the use of ablation devices for local control of unresectable malignant primary and metastatic lung tumors will be discussed by FDA's General & Plastic Surgery Devices Advisory Panel Feb. 28 in Gaithersburg, Md